These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34277465)

  • 1. Aptamers: An Emerging Tool for Diagnosis and Therapeutics in Tuberculosis.
    Srivastava S; Abraham PR; Mukhopadhyay S
    Front Cell Infect Microbiol; 2021; 11():656421. PubMed ID: 34277465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CFP10 and ESAT6 aptamers as effective Mycobacterial antigen diagnostic reagents.
    Tang XL; Zhou YX; Wu SM; Pan Q; Xia B; Zhang XL
    J Infect; 2014 Dec; 69(6):569-80. PubMed ID: 24968239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selection and application of ssDNA aptamers against MPT64 protein in Mycobacterium tuberculosis.
    Qin L; Zheng R; Ma Z; Feng Y; Liu Z; Yang H; Wang J; Jin R; Lu J; Ding Y; Hu Z
    Clin Chem Lab Med; 2009; 47(4):405-11. PubMed ID: 19284297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and application of ssDNA aptamers against glycolipid antigen ManLAM of Mycobacterium tuberculosis for TB diagnosis.
    Tang XL; Wu SM; Xie Y; Song N; Guan Q; Yuan C; Zhou X; Zhang XL
    J Infect; 2016 May; 72(5):573-86. PubMed ID: 26850356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection, characterization, and application of DNA aptamers for detection of Mycobacterium tuberculosis secreted protein MPT64.
    Sypabekova M; Bekmurzayeva A; Wang R; Li Y; Nogues C; Kanayeva D
    Tuberculosis (Edinb); 2017 May; 104():70-78. PubMed ID: 28454652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of Nucleic Acid Aptamers Specific for Mycobacterium tuberculosis.
    Mozioglu E; Gokmen O; Tamerler C; Kocagoz ZT; Akgoz M
    Appl Biochem Biotechnol; 2016 Feb; 178(4):849-64. PubMed ID: 26541162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic evolution and immunoreactivity of aptamers binding to polyclonal antibodies against MPT64 antigen of Mycobacterium tuberculosis.
    Qin LH; Liu ZH; Yang H; Cai JL; Bai WJ; Wang J; Liu JM; Hu ZY
    Eur J Clin Microbiol Infect Dis; 2014 Jul; 33(7):1199-209. PubMed ID: 24500599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
    Ahsan MJ; Ansari MY; Yasmin S; Jadav SS; Kumar P; Garg SK; Aseri A; Khalilullah H
    Infect Disord Drug Targets; 2015; 15(1):32-41. PubMed ID: 25246035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis.
    Chen F; Zhou J; Luo F; Mohammed AB; Zhang XL
    Biochem Biophys Res Commun; 2007 Jun; 357(3):743-8. PubMed ID: 17442275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer against mannose-capped lipoarabinomannan inhibits virulent Mycobacterium tuberculosis infection in mice and rhesus monkeys.
    Pan Q; Wang Q; Sun X; Xia X; Wu S; Luo F; Zhang XL
    Mol Ther; 2014 May; 22(5):940-51. PubMed ID: 24572295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aptamer inhibits Mycobacterium tuberculosis (H37Rv) invasion of macrophage.
    Chen F; Zhang X; Zhou J; Liu S; Liu J
    Mol Biol Rep; 2012 Mar; 39(3):2157-62. PubMed ID: 21643749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.
    Lin MY; Ottenhoff TH
    Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):15-29. PubMed ID: 18393920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application.
    Coppola M; van den Eeden SJF; Robbins N; Wilson L; Franken KLMC; Adams LB; Gillis TP; Ottenhoff THM; Geluk A
    Front Immunol; 2018; 9():308. PubMed ID: 29535713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and application of ssDNA aptamers against H₃₇Rv in the detection of Mycobacterium tuberculosis.
    Aimaiti R; Qin L; Cao T; Yang H; Wang J; Lu J; Huang X; Hu Z
    Appl Microbiol Biotechnol; 2015 Nov; 99(21):9073-83. PubMed ID: 26194558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming the global crisis: "yes, we can", but also for TB ... ?
    Ottenhoff TH
    Eur J Immunol; 2009 Aug; 39(8):2014-20. PubMed ID: 19672895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.